Calidi Biotherapeutics to Present Preclinical Data at ESMO 2026
The company will present data on CLD-401 and its in situ TCE platform, including CLD-501 and CLD-502, highlighting tumor eradication in mice and antigen-dependent T-cell cytotoxicity.
The company will present data on CLD-401 and its in situ TCE platform, including CLD-501 and CLD-502, highlighting tumor eradication in mice and antigen-dependent T-cell cytotoxicity.